Zalicus Inc Com (NASDAQ:ZLCS)

CAPS Rating: 3 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.


Player Avatar thecyberguy (71.02) Submitted: 6/5/2008 2:37:32 PM : Underperform Start Price: $23.10 ZLCS Score: +133.11


Member Avatar shazzan415 (< 20) Submitted: 1/4/2010 3:48:12 PM
Recs: 0

these guys just had a merger and named a new CEO ; At least two of the last companies the New CEO ran were sold to phizer. $0.84 is a deal

Featured Broker Partners